Most Active Stocks as The Market Starts The New Year Off on a Bull run!

Thu Jan 3, 2013 8:30am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130103:nPn1030774


NEW YORK,  January 3, 2013  /PRNewswire/ --

Markets were seen soaring yesterday as a fiscal cliff deal was reached. The DOW
closed up 300 points from the previous close as the NSADAQ saw gains of over 3%.
Investors realized the importance of yesterday's deal and the markets saw a move
that hasn't been seen in weeks. The Stock Freak has a team of well diverse
market professionals that has combined experience of over 30 years that today
are providing members with a quick research report on 5 companies.

Pfizer Inc (NYSE:PFE) - There was a total of 10 Insider transactions on  Dec
28th  2012. The Biggest Trade was from Chairman and CEO  Ian Read  who purchased
416 shares at a price per share of  $24.89  for a total cost of  $ 10,354.20

Whether bull or bear The Stock Freak has got you covered! Sign up to receive our
free newsletters and stay up to date with stocks on the run. 
http://www.TheStockFreak.com

Keycorp (NYSE:KEY) - On  Dec 31st  2012 Kristen Manos Director of Keycorp bought
11,276 shares

World Moto (OTC:FARE)  World Moto has had a big volume week so far. The stock
traded over 20 million shares yesterday and closed up 8% from the previous day's
closing price.

Amr Corp (OTC:AAMRQ) - American airlines although in Bankruptcy still continues
to trade heavy volume. The stock traded over 5 million shares yesterday and
closed the day up 8%.

Amarantus Biosciences  (OTC:AMBS) - AMBS had a massive day in volume yesterday
trading nearly 10 million shares over its average daily volume. The stock closed
up 30% for the first trading day in 2013. Amarantus BioSciences is a
development-stage biotechnology company, focuses on the discovery and
development of therapeutic proteins and biologics for the treatment of
Parkinson's disease.

To find similar research reports that are available for free follow the link
below and sign up at  http://www.TheStockFreak.com 

Disclosure: TheStockFreak.com is not a registered investment advisor and nothing
contained in any materials should be construed as a recommendation to buy or
sell securities. Investors should always conduct their own due diligence with
any potential investment. The Stock Freak is a wholly owned entity of a
financial public relations firm. Please read our report and visit our website,
for complete risks and disclosures.

SOURCE   www.thestockfreak.com


Contact: Info@thestockfreak.com, 433 plaza real Suite 275, Boca Raton, Fl,
33432, +1-561-372-8342
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.